Safety and Efficacy of MEDI0457 Plus Durvalumab in Patients With Human Papillomavirus-associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Charu AggarwalNabil F SabaAlain Patrick AlgaziAmmar SukariTanguy Y SeiwertMissak HaigentzMercedes PorosnicuMarcelo R BonomiJean BoyerMark T EsserLily I ChengSonia AgrawalEmily C JenningsNicholas M DurhamKarl FraserDelphine LissaMaozhen GongNatalia CeaicovscaiaAmaya Gasco HernandezRakesh KumarPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
MEDI0457 plus durvalumab was well tolerated. While the primary efficacy endpoint was not reached, clinical benefit was encouraging.